(EVH) Evolent Health - Overview
Stock: Specialty Care, Platform, Analytics, Software, Cost Management
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 75.0% |
| Relative Tail Risk | -18.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.54 |
| Alpha | -81.36 |
| Character TTM | |
|---|---|
| Beta | 0.601 |
| Beta Downside | 0.149 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.60% |
| CAGR/Max DD | -0.60 |
Description: EVH Evolent Health January 20, 2026
Evolent Health, Inc. (NYSE: EVH) delivers specialty care-management services across oncology, cardiology and musculoskeletal conditions, leveraging a unified platform that supports health-plan administration and value-based care infrastructure.
Its service suite includes health-plan operations, pharmacy-benefits management, risk-management analytics, reporting, and leadership consulting, all powered by the proprietary Identifi technology that aggregates clinical and financial data, orchestrates care workflows, and drives patient engagement.
The company also offers a total-cost-of-care management approach and the Machinify Auth platform, which applies generative-AI techniques to automate prior-authorization and other administrative tasks.
Founded in 2011 and headquartered in Arlington, Virginia, Evolent operates primarily in the United States and is classified under the Health Care Technology sub-industry.
Recent performance indicators (FY 2023) show revenue of roughly $1.2 billion, a year-over-year growth rate of 12 %, and an adjusted EBITDA margin near 6 %, reflecting steady uptake of value-based contracts.
Key sector drivers include the accelerating shift toward value-based reimbursement models, a 5 % annual increase in Medicare Advantage enrollment, and heightened adoption of AI-enabled care coordination tools across health-system networks.
For a deeper dive into EVH’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -128.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -7.18 > 1.0 |
| NWC/Revenue: 6.82% < 20% (prev 0.82%; Δ 6.00% < -1%) |
| CFO/TA -0.01 > 3% & CFO -36.2m > Net Income -128.2m |
| Net Debt (965.7m) to EBITDA (11.9m): 81.25 < 3 |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.1m) vs 12m ago -0.69% < -2% |
| Gross Margin: 18.42% > 18% (prev 0.16%; Δ 1826 % > 0.5%) |
| Asset Turnover: 82.90% > 50% (prev 98.50%; Δ -15.60% > 0%) |
| Interest Coverage Ratio: -1.86 > 6 (EBITDA TTM 11.9m / Interest Expense TTM 45.2m) |
Altman Z'' -1.61
| A: 0.06 (Total Current Assets 570.1m - Total Current Liabilities 429.9m) / Total Assets 2.45b |
| B: -0.36 (Retained Earnings -886.2m / Total Assets 2.45b) |
| C: -0.03 (EBIT TTM -83.8m / Avg Total Assets 2.48b) |
| D: -0.55 (Book Value of Equity -887.4m / Total Liabilities 1.61b) |
| Altman-Z'' Score: -1.61 = D |
Beneish M -3.20
| DSRI: 1.14 (Receivables 386.6m/407.9m, Revenue 2.05b/2.46b) |
| GMI: 0.87 (GM 18.42% / 15.96%) |
| AQI: 0.98 (AQ_t 0.74 / AQ_t-1 0.75) |
| SGI: 0.83 (Revenue 2.05b / 2.46b) |
| TATA: -0.04 (NI -128.2m - CFO -36.2m) / TA 2.45b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of EVH shares?
Over the past week, the price has changed by -5.26%, over one month by -22.53%, over three months by -52.85% and over the past year by -70.15%.
Is EVH a buy, sell or hold?
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EVH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.2 | 200% |
| Analysts Target Price | 9.2 | 200% |
| ValueRay Target Price | 2.1 | -30.4% |
EVH Fundamental Data Overview February 03, 2026
P/S = 0.1812
P/B = 0.4293
P/EG = -1.37
Revenue TTM = 2.05b USD
EBIT TTM = -83.8m USD
EBITDA TTM = 11.9m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 23.1m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 965.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.34b USD (372.3m + Debt 1.08b - CCE 116.7m)
Interest Coverage Ratio = -1.86 (Ebit TTM -83.8m / Interest Expense TTM 45.2m)
EV/FCF = -19.48x (Enterprise Value 1.34b / FCF TTM -68.7m)
FCF Yield = -5.13% (FCF TTM -68.7m / Enterprise Value 1.34b)
FCF Margin = -3.34% (FCF TTM -68.7m / Revenue TTM 2.05b)
Net Margin = -6.24% (Net Income TTM -128.2m / Revenue TTM 2.05b)
Gross Margin = 18.42% ((Revenue TTM 2.05b - Cost of Revenue TTM 1.68b) / Revenue TTM)
Gross Margin QoQ = 20.81% (prev 22.59%)
Tobins Q-Ratio = 0.55 (Enterprise Value 1.34b / Total Assets 2.45b)
Interest Expense / Debt = 1.52% (Interest Expense 16.5m / Debt 1.08b)
Taxrate = 21.0% (US default 21%)
NOPAT = -66.2m (EBIT -83.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.33 (Total Current Assets 570.1m / Total Current Liabilities 429.9m)
Debt / Equity = 1.29 (Debt 1.08b / totalStockholderEquity, last quarter 842.2m)
Debt / EBITDA = 81.25 (Net Debt 965.7m / EBITDA 11.9m)
Debt / FCF = -14.06 (negative FCF - burning cash) (Net Debt 965.7m / FCF TTM -68.7m)
Total Stockholder Equity = 918.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.17% (Net Income -128.2m / Total Assets 2.45b)
RoE = -13.95% (Net Income TTM -128.2m / Total Stockholder Equity 918.8m)
RoCE = -4.25% (EBIT -83.8m / Capital Employed (Equity 918.8m + L.T.Debt 1.05b))
RoIC = -3.76% (negative operating profit) (NOPAT -66.2m / Invested Capital 1.76b)
WACC = 2.98% (E(372.3m)/V(1.45b) * Re(8.13%) + D(1.08b)/V(1.45b) * Rd(1.52%) * (1-Tc(0.21)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
Fair Price DCF = unknown (Cash Flow -68.7m)
EPS Correlation: -51.42 | EPS CAGR: -17.75% | SUE: -0.39 | # QB: 0
Revenue Correlation: 75.78 | Revenue CAGR: 19.18% | SUE: 1.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=-0.012 | Revisions Net=-4 | Analysts=5
EPS next Year (2026-12-31): EPS=0.30 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+387.7% | Growth Revenue=+27.1%